10x Genomics (NASDAQ:TXG) stock slid 14% Wednesday amid news that Illumina (ILMN) has acquired single cell analysis technology company Fluent BioSciences and a downgrade by Deutsche Bank.

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Oxford Nanopore Technologies announced its expanded collaboration with 10x Genomics, Inc. to enable seamless compatibility between their latest technologies, bringing more accurate, cost-effective and ...

We offer a range of services, including single cell RNA sequencing and spatial transcriptomics. Our facility is equipped with state-of-art instruments, including the 10X Genomics Chromium X which ...

In 2024, 10x Genomics worked to cement its status as “the single-cell analysis company,” making upgrades and additions to its portfolio of tools used by researchers in academia and industry to ...

Single-cell transcriptomics has revolutionized the study of cellular diversity and function by enabling gene expression ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

today affirmed their plans to proceed with development and future release of their Evercode™ single cell chromatin products. This comes on the heels of Parse invalidating the patents that 10x ...

The Single-Cell Analytics Innovation Lab (SAIL ... into an easy-to-use package to perform and develop droplet microfluidics experiment. Xenium by 10X Genomics In Situ platform enables subcellular ...